Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity.
Sci Adv
January 2025
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
A major limiting factor in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues. CAR T cells against GD2 induced rapid, fatal neurotoxicity because of CAR recognition of GD2 normal mouse brain tissue. To improve the selectivity of the CAR T cell, we engineered a synthetic Notch receptor that selectively expresses the CAR upon binding to P-selectin, a cell adhesion protein overexpressed in tumor neovasculature.
View Article and Find Full Text PDFHSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
Blood
January 2025
Hospital Santa Creu i Sant Pau, Barcelona, Spain.
CD30-directed CART cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the non-soluble part of CD30, and the manufacturing process includes a modulation of ex vivo T cell activation, as well as the addition of interleukin-21 to IL-7 and IL-15 to promote stemness of T cells.
View Article and Find Full Text PDF[Patient with diffuse large B-cell lymphoma: a good example of network in care.].
Recenti Prog Med
January 2025
UO Ematologia, Ospedale San Bortolo, Vicenza.
Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Success of CAR-T treatment heavily relies on early referral to the CAR-T center, on a short time of infusion of CAR-T cells from the lymphocyte collection and on a reduced burden of disease. Here we describe the case of a patient with diagnosis of High-grade B-cell lymphoma with MYC and BCL6 rearrangements, transformed from marginal zone lymphoma, referred with a refractory and rapidly progressive disease.
View Article and Find Full Text PDFIntroduction: Pseudoprogression is a complication observed following CAR-T therapy that can mimic disease progression; however, its incidence is not well defined. This phenomenon is driven by a robust inflammatory response due to the recognition of CAR-T cells targeting the lymphoma. Misinterpreting pseudoprogression as true disease progression could result in unnecessary alterations to the treatment regimen.
View Article and Find Full Text PDFDigit Amputation Secondary to COVID-19-Induced Raynaud's Phenomenon.
Cureus
December 2024
Internal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, PRT.
Raynaud's phenomenon (RP) is characterized by episodic vasospasm of the small blood vessels, primarily affecting the fingers and toes. Management includes lifestyle modifications, pharmacological treatments, and in severe cases, surgical interventions. Here we report a case of an 80-year-old male patient with a history of hypertension, dyslipidemia, obesity, and atrial fibrillation who presented to the emergency department with edema, cyanosis, and intense pain in the fingers of both hands following a mild COVID-19 infection (no dyspnea or hypoxemia).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!